- Ticker
- ACTI.ST
- Price
- 1.08
- Stock movement down
- -0.02 (-2.18%)
- Company name
- Active Biotech AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 244.40M
- Ent value
- 217.90M
- Price/Sales
- -
- Price/Book
- 7.88
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -23.23%
- 3 year return
- -22.78%
- 5 year return
- -16.25%
- 10 year return
- -28.12%
Last updated: 2022-08-25
DIVIDENDS
ACTI.ST does not pay dividends
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 7.88 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 227.14M |
| EPS (TTM) | -0.24 |
| FCF per share (TTM) | -0.23 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -54.20M |
| Net income (TTM) | -54.40M |
| EPS (TTM) | -0.24 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 37.80M |
| Net receivables | 3.60M |
| Total current assets | 41.50M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 42.30M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 11.10M |
| Total liabilities | 11.30M |
| Shareholder's equity | 31.00M |
| Net tangible assets | 30.80M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -52.87M |
| Capital expenditures (TTM) | 200.00K |
| Free cash flow (TTM) | -53.07M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -175.48% |
| Return on Assets | -128.61% |
| Return on Invested Capital | -175.48% |
| Cash Return on Invested Capital | -171.18% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.05 |
| Daily high | 1.10 |
| Daily low | 1.05 |
| Daily Volume | 174K |
| All-time high | 321.94 |
| 1y analyst estimate | 2.40 |
| Beta | 0.75 |
| EPS (TTM) | -0.24 |
| Dividend per share | - |
| Ex-div date | 17 Apr 1998 |
| Next earnings date | 3 Nov 2022 |
Downside potential
Loading...
Downside potential data
| ACTI.ST | S&P500 | |
| Current price drop from All-time high | -99.67% | -12.18% |
| Highest price drop | -99.72% | -56.47% |
| Date of highest drop | 8 Mar 2022 | 9 Mar 2009 |
| Avg drop from high | -91.27% | -11.38% |
| Avg time to new high | 6417 days | 12 days |
| Max time to new high | 6416 days | 1805 days |
COMPANY DETAILS
Marketcap
244.40M
Marketcap category
Small-cap
Description
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
Employees
9
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Lund, June 1, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today the successful completion of the first stage of a Simon 2 stage phase IIa clinical trial of naptumomab...
June 1, 2022
The Annual General Meeting of Active Biotech was held on May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting was carried out through postal voting, without any physical att...
May 19, 2022
Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of mye...
May 18, 2022
Active Biotech's Annual Report 2021 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. Download as PDF Lund, April 28, 2022 Active Biotech AB...
April 28, 2022
Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has issued a decision to grant Active Biotech’s patent related to use of laquinimod ...
April 26, 2022
FIRST QUARTER IN BRIEF Dr. Erik Vahtola appointed Chief Medical Officer (Jan 01)First patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma (Feb 07)Active ...
April 21, 2022
The shareholders of Active Biotech AB (publ) are invited to the Annual General Meeting of shareholders to be held on Thursday, May 19, 2022. Due to the situation resulting from the Corona virus, the M...
April 20, 2022
The number of shares and votes in Active Biotech has changed as a result of allotment of performance shares under the company’s incentive program for the company’s employees (Plan 2020/2024). Today, t...
March 31, 2022
The correction refers to the administrative costs for the period January – December 2021 that due to oversight have been stated too low. The incorrect amount was SEK 14,0 M, the correct amount is SEK ...
March 25, 2022
FOURTH QUARTER IN BRIEF In 2021, we made substantial progress in our projects to address unmet medical need in hematological cancers and inflammatory eye disorders. The fourth quarter in particular pr...
February 9, 2022
Next page